Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Coelho Dos Reis Jordana Grazziela A, Ferreira Geovane Marques, Lourenço Alice Aparecida, Ribeiro Ágata Lopes, da Mata Camila Pacheco da Silveira Martins, de Melo Oliveira Patrícia, Marques Daisymara Priscila de Almeida, Ferreira Linziane Lopes, Clarindo Felipe Alves, da Silva Murillo Ferreira, Filho Heitor Portella Póvoas, Oliveira Nilson Roberto Ribeiro, Sodré Maisah Meyhr D'Carmo, Gadelha Sandra Rocha, Albuquerque George Rego, Maciel Bianca Mendes, Mariano Ana Paula Melo, Silva Mylene de Melo, Fontana Renato, Marin Lauro Juliano, Carlos Renata Santiago Alberto, Lopes Amanda Teixeira Sampaio, Ferreira Fabrício Barbosa, Dos Santos Uener Ribeiro, Santana Íris Terezinha Santos de, Fehlberg Hllytchaikra Ferraz, Rezende Rachel Passos, Dias João Carlos T, Gross Eduardo, Goulart Gisele Assis Castro, Santiago Marie Gabriele, de Lemos Ana Paula Motta Lavigne, da Conceição Aline O, Romano Carla Cristina, de Carvalho Luciana Debortoli, Martins Filho Olindo Assis, Quadros Claudio Almeida, Morris David L, Valle Sarah J
Аннотация
METHOD: Tracheal aspirate samples from COVID-19 patients were collected following next of kin consent and mucolysis, rheometry and cytokine analysis using Luminex kit was performed.
RESULTS: BromAc® displayed a robust mucolytic effect in a dose dependent manner on COVID-19 sputum ex vivo. BromAc® showed anti-inflammatory activity, reducing the action of cytokine storm, chemokines including MIP-1alpha, CXCL8, MIP-1b, MCP-1 and IP-10, and regulatory cytokines IL-5, IL-10, IL-13 IL-1Ra and total reduction for IL-9 compared to NAC alone and control. BromAc® acted on IL-6, demonstrating a reduction in G-CSF and VEGF-D at concentrations of 125 and 250 µg.
CONCLUSION: These results indicate robust mucolytic and anti-inflammatory effect of BromAc® ex vivo in tracheal aspirates from critically ill COVID-19 patients, indicating its potential to be further assessed as pharmacological treatment for COVID-19.